We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Gene-Triggered Transporter Approach Causes Breast Cancer Cells to Self-Destruct

By LabMedica International staff writers
Posted on 09 Mar 2011
Irish Scientists have demonstrated that they can deliver a gene directly into breast cancer cells causing them to self-destruct, using a novel, minute gene transport system.

The study's findings were published February 28, 2011, in the International Journal of Pharmaceutics. Employing a transport system called a designer biomimetic vector (DBV), Dr. More...
Helen McCarthy, from Queen's University Belfast (Ireland) School of Pharmacy, funded by the Breast Cancer Campaign (London, UK), packed a gene into a nanoparticle 400 times smaller than the width of a human hair, allowing it to be delivered right into breast cancer cells in the laboratory.

The gene called iNOS (induction of nitric oxide synthase), is targeted specifically to breast cancer cells using the DBV where it forces the cells to generate lethal nitric oxide; either killing the cells outright or making them more susceptible to being destroyed by chemotherapy and radiotherapy. As this technique leaves normal healthy breast cells unaffected, this would overcome many of the toxic side effects of current treatments.

Additional study is needed but it could be trialed in patients in as little as five years. Dr. McCarthy's next step is to convert the nanoparticles into a dried powder that could be easily transported and reconstituted before being administered to patients.

Dr. McCarthy commented, "A major stumbling block to using gene therapy in the past has been the lack of an effective delivery system. Combining the designer biomimetic vector with the iNOS gene has proved successful in killing breast cancer cells in the laboratory. In the long term, I see this being used to treat people with metastatic breast cancer that has spread to the bones, ideally administered before radiotherapy and chemotherapy.”

Dr. Lisa Wilde, research information senior manager, Breast Cancer Campaign said, "Gene therapy could potentially be an exciting avenue for treating breast cancer. Although at an early stage, Dr. McCarthy's laboratory research shows that this system for delivering toxic genes to tumor cells holds great promise and we look forward to seeing how it is.”

Related Links:
Queen's University Belfast
Breast Cancer Campaign



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.